STELIOS PAPADOPOULOS
CIK 1202098 · last filed 2026-05-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$69.48M
Companies
7
Total Filings
113
Lifetime Open-Market Net
-$16.51M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| EXEL | Director | 1,197,595 | $52.94 | $63.39M | -$15.23M | 38 | 2026-05-29 |
| OVID | Director | 217,578 | $2.22 | $483.0K | $0 | 3 | 2026-04-09 |
| Regulus Therapeutics Inc. (RGLS) Delisted | Director | 0 | $8.16 | $0 | $2.77M | 34 | 2025-06-27 |
| BIIB | Director | 27,470 | $203.81 | $5.60M | -$5.43M | 16 | 2022-06-17 |
| Eucrates Biomedical Acquisition Corp. (EUCRU) Delisted | Director | 2,619,906 | $10.02 | $26.25M | $0 | 1 | 2020-11-27 |
| BG Medicine, Inc. (BGMD) Delisted | Director | 296,928 | — | — | $1.02M | 7 | 2013-06-14 |
| ANADYS PHARMACEUTICALS INC (ANDS) Delisted | Director | 814,206 | — | — | $369.5K | 10 | 2011-05-27 |
Recent Filings · Page 7 of 12
113 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2017-06-09 | BIIB | Grant (A) | +1,740 | $0 | EDGAR |
| 2017-06-02 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-05-30 | EXEL | Grant (A) | +5,843 | $0 | EDGAR |
| 2017-05-26 | EXEL | Grant (A) | +5,843 | $0 | EDGAR |
| 2017-03-23 | Regulus Therapeutics Inc. (RGLS) Delisted | Buy (P) | +500,000 | $607.9K | EDGAR |
| 2017-03-21 | EXEL | Mixed | — | -$111.3K | EDGAR |
| 2016-06-09 | BIIB | Grant (A) | +1,590 | $0 | EDGAR |
| 2016-06-03 | Regulus Therapeutics Inc. (RGLS) Delisted | Grant (A) | — | $0 | EDGAR |
| 2016-05-26 | EXEL | Grant (A) | — | $0 | EDGAR |
| 2016-01-05 | EXEL | Grant (A) | +15,071 | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.